Matthew R. Weir, MD, is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School Of Medicine.
Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, blood pressure salt sensitivity, biomeasures of cardiovascular disease, and preventing allograft nephropathy in transplant recipients. He has written more than 500 manuscripts and book chapters about these topics. He has edited five books: including, “Medical Management of Kidney Transplantation” and “Hypertension”. He has presented at numerous international scientific association meetings, hospitals, and medical schools.
Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the American Journal of Kidney Disease, the Journal of the American Society of Nephrology, and Archives of Internal Medicine. He is on the editorial board of 15 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology and Associate Editor of the American Journal of Nephrology and Clinical Nephrology. He is supported by two NIH grants from NIDDK and investigator-initiated grants from industry. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation.
Dr. Weir received his medical degree from the University of Virginia, Charlottesville. He completed his internship and residency programs in medicine at the Waterbury and Yale-New Haven Hospitals in Connecticut, and completed his nephrology training at the Brigham and Women’s Hospital, Harvard Medical School, in Boston, Massachusetts. He then moved to the University of Maryland where he has been a full time faculty member since 1983.
One of my main research interests is cardiovascular disease associated with chronic kidney disease. Our group is involved in a series of clinical trials to evaluate biomeasures of cardiovascular disease in patients with chronic kidney disease, as well as to better describe optimum levels of blood pressure and use of various antihypertensive medications in delaying progression of kidney disease. These studies are ongoing in patients with non-diabetic as well as diabetic kidney disease. In addition, we have ongoing trials to evaluate the etiologies of cardiovascular disease and progressive loss of kidney function in patients who have received kidney transplants. These data are important in order to evaluate optimal means of preventing cardiovascular disease, as well as better forms of immunosuppression to limit the development of allograft nephropathy and graft loss. Another research effort evaluates molecular mechanisms behind blood pressure salt sensitivity which may translate into future therapeutic strategies for hypertension.
Cardiovascular disease associated with chronic kidney disease and prevention of progressive renal disease. Additionally, clinical care of kidney transplant recipients.